Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Why Bio-Techne (TECH) Stock Is Trading Up Today

June 24, 2026 at 11:36 AM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

TECH Cover Image

What Happened?

Shares of life sciences company Bio-Techne (NASDAQ: TECH) jumped 5.4% in the morning session after TD Cowen reiterated a Buy rating and a $65.00 price target on the stock.

The investment firm acknowledged that near-term challenges persist in the Life Science Tools sector due to macro-level economic factors. However, TD Cowen stated that Bio-Techne's wide range of reagents and instruments represents one of the highest quality portfolios in the industry. The firm highlighted that the company's products serve many of the fastest-growing areas within the sector, supporting a positive outlook for long-term growth.

Is now the time to buy Bio-Techne? Access our full analysis report here, it’s free.

What Is The Market Telling Us

Bio-Techne’s shares are very volatile and have had 20 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The biggest move we wrote about over the last year was 11 months ago when the stock dropped 6.5% on the news that the company reported its fourth-quarter fiscal 2025 results, which included a significant net loss driven by a large impairment charge.

The company posted a net loss of $17.68 million, a sharp reversal from the $40.59 million in net income recorded a year ago. This loss resulted from an $83.1 million impairment charge linked to the divestiture of its Exosome Diagnostics business. An impairment charge is an accounting entry used when an asset's value falls below its recorded worth. Furthermore, the company's gross margin tightened and it recorded an operating loss of $23.9 million, compared to an operating profit of $45.8 million in the prior year. The Diagnostics and Spatial Biology division also experienced a 1% decrease in sales.

Bio-Techne is flat since the beginning of the year, and at $59.51 per share, it is trading 16.6% below its 52-week high of $71.38 from January 2026. Investors who bought $1,000 worth of Bio-Techne’s shares 5 years ago would now be looking at only $541.56.

ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.

These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article